What are FcRn antagonist drugs?

FcRn antagonist drugs are pharmacologic agents that share a common mechanism (typically targeting FcRn (neonatal Fc receptor)). 2 are currently marketed, with 2 more in clinical development.

What are the marketed FcRn antagonist drugs?

Marketed FcRn antagonist drugs include UPLIZNA, Efgartigimod PH20 SC.

FcRn antagonist

2 marketed 2 in Phase 3

This page covers all FcRn antagonist drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting FcRn (neonatal Fc receptor), Neonatal Fc receptor (FcRn).

Targets

FcRn (neonatal Fc receptor) · Neonatal Fc receptor (FcRn)

Marketed (2)

UPLIZNA · Amgen · Immunology
UPLIZNA is a neonatal Fc receptor (FcRn) antagonist that blocks the recycling and extends the half-life of pathogenic immunoglobulins, leading to their increased clearance from circulation.
Efgartigimod PH20 SC · argenx · Immunology
Efgartigimod is an IgG Fc fragment that binds to the neonatal Fc receptor (FcRn) to reduce circulating immunoglobulin levels, particularly IgG antibodies.

Phase 3 pipeline (2)

IMVT-1402 · Immunovant Sciences GmbH · Immunology
IMVT-1402 is a neonatal Fc receptor (FcRn) antagonist that reduces circulating immunoglobulin levels by blocking FcRn-mediated recycling of IgG antibodies.
Empasiprubart IV · argenx · Immunology
Empasiprubart is a FcRn (neonatal Fc receptor) antagonist that reduces the recycling and extends the half-life of IgG antibodies, enhancing their therapeutic activity.